Which are the top 20 pharma stocks in 2018?
This is a list of the top-20 stocks in the pharma sector.
It’s based on data from the Australian Stock Exchange (ASX) and Thomson Reuters data.
Key words: pharma,stock,stock indices,stocks index,traders,indexed index source ABC World News title 5 reasons to buy stocks article 5.
Pfizer Inc. PFE -0.20% Pfizer shares have soared in 2017 and 2018, outperforming the broader market.
This year, the stock gained almost 1% for the year to date, while its share price is currently around $60 a share.
However, Pfizer’s stock price has fallen in recent years as it struggles to turn a profit.
In 2018, Pfizers shares are up only 0.4%, from $69.68 in 2018 to $71.08 in 2019.
If the stock returns to the $70s or $80s range, Pfishers stock could rise to the top of the list.
Abbott Laboratories ABNL -1.14% Abbott Laboratories is one of the world’s largest drug companies.
The company is one the most well-known and profitable in the world, with revenues of about $3.5 trillion.
However it has been in financial trouble over the last few years.
Its shares have lost more than half of their value since 2017, after falling by almost $1 billion in 2018.
If Abbott stays at the current level of $65 a share, it could easily rise to a higher price, but it’s not clear whether the stock will rise much further this year.
GlaxoSmithKline GSK -0,839% The US drugmaker is currently experiencing a prolonged period of low growth.
Its profits have been reduced by more than 90% since 2009, when it started producing the first version of its blockbuster hepatitis C drug.
The drugmaker has since been losing money on every product it sells.
The most recent round of company-wide layoffs in the US are being blamed on a downturn in sales.
If Glaxos shares continue to drop, it will be a difficult situation for the company.
Valeant Pharmaceuticals VAXXY -0 for 2018 source ABC Home article Valeant’s stock has dropped more than 70% since 2016, and it is one that investors should be wary of.
The stock is now trading at less than half its pre-crisis value, with some analysts predicting it will fall below $15 by 2021.
Valeants shares fell nearly 2,000% last year, falling from $22 to just over $14 a share by the end of 2018.
Valeans stock price is now below $9 a share in 2019, and there are concerns that Valeant may have to raise more money from its shareholders.
Abbott Labs ABNL +0.19% The Australian company is in the midst of a $4 billion restructuring effort.
This has caused some problems for the Australian business, with the company recently announcing it will cut 2,700 jobs.
Abbott is one company that may see its stock price fall, especially if it continues to struggle to generate profits.
Pfizers Inc. PfYS -1 article Pfizer was founded in 1896 in Germany by a pharmaceutical chemist.
Since then, the company has grown to become the world leader in the production and sale of pharmaceuticals.
In recent years, Pfizs share price has gone up a lot, with shares recently increasing by nearly 3,500%.
If the company continues to fall, it would be an unfortunate situation for Pfizys stock price.
Source: The Australian Financial Review